Ignite Creation Date:
2025-12-25 @ 4:54 AM
Ignite Modification Date:
2026-02-21 @ 10:09 PM
Study NCT ID:
NCT02879318
Status:
COMPLETED
Last Update Posted:
2025-03-24
First Post:
2016-08-22
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma
Sponsor:
Canadian Cancer Trials Group
Organization:
Organization Data
Organization:
Class:
NETWORK
Study ID:
PA7
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
NETWORK
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |